Citations

Clear

382 citation(s) found for "Shapiro, R".

Update on Gender Equity in Immunology, 2001 to 2016
Kovats, Susan , Parent, Michelle A., Gaffen, Sarah L. , Hedrick, Catherine C. , Denzin, Lisa , Raghavan, Malini , Stephens, Robin , Shapiro, Virginia Smith , Kovats, Susan , Raghavan, Malini , Jain, Pooja

Mayo Clinic

The Journal of Immunology | October 18, 2016 | Volume: 197 | Issue: 10 | Pages: 3751-3753

10.4049/jimmunol.1601644 | PMID 27798172 Get It

Abstract In 2001, The American Association of Immunologists Committee on the Status of Women conducted a survey examining the percentage of women faculty members within immunology departments or women in immunology graduate programs across 27 institutions in the United States, comparing it to the percentage of women receiving a Ph.D. Here, we examine the representation of women across these same 27 immunology departments and programs to examine changes in gender equity over the last 15 years.
Pipeline for uncoilable or failed aneurysms: 3-year follow-up results
Becske, Tibor , Potts, Matthew B. , Shapiro, Maksim , Kallmes, David F. , Brinjikji, Waleed , Saatçi, Işıl , McDougall, Cameron G. , Szikora, István , Moran, Christopher J. , Woo, Henry H. , Berez, Aaron L., Cher, Daniel , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Berentei, Zsolt, Marosföi, Miklós , Cekirge, Saruhan H., Nelson, Peter K. , Lanzino, Giuseppe , Lopes, Demetrius K. , Levy, Elad I. , Fiorella, David , Siddiqui, Adnan H , Szikora, Istvan

Mayo Clinic

Journal of Neurosurgery | October 14, 2016 | Volume: 127 | Issue: 1 | Pages: 81-88

10.3171/2015.6.jns15311 | PMID 27739944 Get It

OBJECTIVEThe long-term effectiveness of endovascular treatment of large and giant wide-neck aneurysms using traditional endovascular techniques has been disappointing, with high recanalization and re-treatment rates. Flow diversion with the Pipeline Embolization Device (PED) has been recently used as a stand-alone therapy for complex aneurysms, showing significant improvement in effectiveness while demonstrating a similar safety profile to stent-supported coil treatment. However, relatively little is known about its long-term safety and effectiveness. Here the authors report on the 3-year safety and effectiveness of flow diversion with the PED in a prospective cohort of patients with large and giant internal carotid artery aneurysms enrolled in the Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial.METHODSThe PUFS trial is a prospective study of 107 patients with 109 aneurysms treated with the PED. Primary effectiveness and safety end points were demonstrated based on independently monitored 180-day clinical and angiographic data. Patients were enrolled in a long-term follow-up protocol including 1-, 3-, and 5-year clinical and imaging follow-up. In this paper, the authors report the midstudy (3-year) effectiveness and safety data.RESULTSAt 3 years posttreatment, 74 subjects with 76 aneurysms underwent catheter angiography as required per protocol. Overall, complete angiographic aneurysm occlusion was observed in 71 of these 76 aneurysms (93.4% cure rate). Five aneurysms were re-treated, using either coils or additional PEDs, for failure to occlude, and 3 of these 5 were cured by the 3-year follow-up. Angiographic cure with one or two treatments of Pipeline embolization alone was therefore achieved in 92.1%. No recanalization of a previously completely occluded aneurysm was noted on the 3-year angiograms. There were 3 (2.6%) delayed device- or aneurysm-related serious adverse events, none of which led to permanent neurological sequelae. No major or minor late-onset hemorrhagic or ischemic cerebrovascular events or neurological deaths were observed in the 6-month through 3-year posttreatment period. Among 103 surviving patients, 85 underwent functional outcome assessment in which modified Rankin Scale scores of 0–1 were demonstrated in 80 subjects.CONCLUSIONSPipeline embolization is safe and effective in the treatment of complex large and giant aneurysms of the intracranial internal carotid artery. Unlike more traditional endovascular treatments, flow diversion results in progressive vascular remodeling that leads to complete aneurysm obliteration over longer-term follow-up without delayed aneurysm recanalization and/or growth.Clinical trial registration no.: NCT00777088 (clinicaltrials.gov)
A novel semiquantitative assessment of right ventricular systolic function with a modified subcostal echocardiographic view
Alvarez, Andres Borja, Danaraj, Jonathan, Freeman, Michelle L., Lee, Augustine S. , Mookadam, Farouk , Shapiro, Brian P. , Díaz-Gómez, José L , Danaraj, Jonathan J, Ramakrishna, Harish , Díaz‐Gómez, José L. , Mookadam, Farouk

Mayo Clinic

Echocardiography | October 14, 2016 | Volume: 34 | Issue: 1 | Pages: 44-52

10.1111/echo.13400 | PMID 27739100 Get It

ObjectivesThe tricuspid annular plane systolic excursion (TAPSE) is a validated measure of right ventricular function; however, the apical echocardiographic window varies and has limitations in intensive care unit (ICU) patients receiving mechanical ventilation or those with underlying disease and air entrapment. We aimed to evaluate the subcostal echocardiographic assessment of tricuspid annular kick (SEATAK) as an alternative to TAPSE in critically ill patients.MethodsTo measure SEATAK, we obtained the subcostal inferior vena cava view and used M‐mode to measure excursion of the tricuspid annulus (kick). Analysis was performed with JMP for Bland‐Altman and Spearman correlations.ResultsWe evaluated 45 patients, 26 (57.8%) of whom were women, with a mean age of 60.8 years. We were not able to obtain the apical view to measure TAPSE in 8.9% of the patients. In contrast, SEATAK was measured in all patients. The mean SEATAK and TAPSE were 1.62 cm and 1.93 cm, respectively, with a mean pairwise difference of −0.26 cm (95% CI: −0.19 to −0.35), with the SEATAK value being lower than TAPSE. The overall correlation was strong and significant (ρ = .86, P=.03). The graphical correlation was maintained between TAPSE and SEATAK and the degree of RVF.ConclusionIn patients presenting with RVF in the ICU (or in situations where the apical echocardiographic view is suboptimal for tricuspid annular assessment), SEATAK can be an alternative to TAPSE. Further research is needed to validate and determine the sensitivity and specificity of SEATAK for RVF prognostication.
Cyclin A2 is an RNA binding protein that controls Mre11 mRNA translation
Jeganathan, Karthik B. , Limzerwala, Jazeel F. , Baker, Darren J. , Hamada, Masakazu , Nam, Hyun-Ja, Deursen, Willemijn H. van , Hamada, Naomi, Naylor, Ryan M. , Becker, Nicole A. , Davies, Brian A., Ree, Janine H. van, Mer, Georges , Maher, L. James, Katzmann, David J. , Deursen, Jan M. van , Kanakkanthara, Arun , van Deursen, Willemijn H, van Ree, Janine H, Shapiro, Virginia S, Hamada, Masakazu, Shapiro, Virginia Smith , Jeganathan, Karthik B , Baker, Darren J

Mayo Clinic

Science | September 29, 2016 | Volume: 353 | Issue: 6307 | Pages: 1549-1552

10.1126/science.aaf7463 | PMID 27708105 Get It

Cyclin A2 activates the cyclin-dependent kinases Cdk1 and Cdk2 and is expressed at elevated levels from S phase until early mitosis. We found that mutant mice that cannot elevate cyclin A2 are chromosomally unstable and tumor-prone. Underlying the chromosomal instability is a failure to up-regulate the meiotic recombination 11 (Mre11) nuclease in S phase, which leads to impaired resolution of stalled replication forks, insufficient repair of double-stranded DNA breaks, and improper segregation of sister chromosomes. Unexpectedly, cyclin A2 controlled Mre11 abundance through a C-terminal RNA binding domain that selectively and directly binds Mre11 transcripts to mediate polysome loading and translation. These data reveal cyclin A2 as a mechanistically diverse regulator of DNA replication combining multifaceted kinase-dependent functions with a kinase-independent, RNA binding–dependent role that ensures adequate repair of common replication errors.
A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis
Kazmerchak, Shari E. , O'Connor, Mary I, Shapiro, Shane A. , Heckman, Michael G. , Zubair, Abba C. , O’Connor, Mary I.

Mayo Clinic

The American Journal of Sports Medicine | August 26, 2016 | Volume: 45 | Issue: 1 | Pages: 82-90

10.1177/0363546516662455 | PMID 27566242 Get It

Background: Bone marrow aspirate concentrate (BMAC) is increasingly used as a regenerative therapy for musculoskeletal pathological conditions despite limited evidence-based support. Hypothesis: BMAC will prove feasible, safe, and efficacious for the treatment of pain due to mild to moderate degenerative joint disease of the knee. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: In this prospective, single-blind, placebo-controlled trial, 25 patients with bilateral knee pain from bilateral osteoarthritis were randomized to receive BMAC into one knee and saline placebo into the other. Fifty-two milliliters of bone marrow was aspirated from the iliac crests and concentrated in an automated centrifuge. The resulting BMAC was combined with platelet-poor plasma for an injection into the arthritic knee and was compared with a saline injection into the contralateral knee, thereby utilizing each patient as his or her own control. Safety outcomes, pain relief, and function as measured by Osteoarthritis Research Society International (OARSI) measures and the visual analog scale (VAS) score were tracked initially at 1 week, 3 months, and 6 months after the procedure. Results: There were no serious adverse events from the BMAC procedure. OARSI Intermittent and Constant Osteoarthritis Pain and VAS pain scores in both knees decreased significantly from baseline at 1 week, 3 months, and 6 months ( P ≤ .019 for all). Pain relief, although dramatic, did not differ significantly between treated knees ( P > .09 for all). Conclusion: Early results show that BMAC is safe to use and is a reliable and viable cellular product. Study patients experienced a similar relief of pain in both BMAC- and saline-treated arthritic knees. Further study is required to determine the mechanisms of action, duration of efficacy, optimal frequency of treatments, and regenerative potential. Registration: ClinicalTrials.gov record 12-004459.
Risk Factors for Readmission in Patients With Cancer Comanaged by Hospitalists
Shapiro, Joshua S., Humeniuk, Michael, Siddiqui, Mustaqeem , Bonthu, Neelima, Schroeder, Darrell R. , Kashiwagi, Deanne T. , Siddiqui, Mustaqeem A, Siddiqui, Mustaqeem A , Schroeder, Darrell

Mayo Clinic

American Journal of Medical Quality | August 26, 2016 | Volume: 32 | Issue: 5 | Pages: 526-531

10.1177/1062860616665904 | PMID 27561695 Get It

Little is known about which variables put patients with cancer at risk for 30-day hospital readmission. Comanagement of this often complex patient population by specialists and hospitalists has become increasingly common. This retrospective study examined inpatients with cancer comanaged by hospitalists, hematologists, and oncologists to determine the rate of readmission and factors associated with readmission. Patients in this cohort had a readmission rate of 23%. Patients who were discharged to a skilled nursing facility (odds ratio [OR] = 0.34) or hospice (OR = 0.11) were less likely to have 30-day readmissions, whereas patients who had surgery (OR = 3.16) during their index admission were more likely. Other factors, including patient demographics, cancer types, and hospitalization interventions and events, did not differ between patients who were readmitted and those who were not. These findings contribute to a growing body of literature identifying risk factors for readmission in medical oncology and hematology patients.
HDAC3 Is Required for the Downregulation of RORγt during Thymocyte Positive Selection
Philips, Rachael L. , Chen, Meibo W., McWilliams, Douglas C., Belmonte, Paul , Constans, Megan, Belmonte, Paul J, Constans, Megan M, Shapiro, Virginia Smith , Belmonte, Paul J

Mayo Clinic

The Journal of Immunology | June 9, 2016 | Volume: 197 | Issue: 2 | Pages: 541-554

10.4049/jimmunol.1502529 | PMID 27279370 Get It

Abstract To generate functional peripheral T cells, proper gene regulation during T cell development is critical. In this study, we found that histone deacetylase (HDAC) 3 is required for T cell development. T cell development in CD2-icre HDAC3 conditional knockout (cKO) mice (HDAC3-cKO) was blocked at positive selection, resulting in few CD4 and CD8 T cells, and it could not be rescued by a TCR transgene. These single-positive thymocytes failed to upregulate Bcl-2, leading to increased apoptosis. HDAC3-cKO mice failed to downregulate retinoic acid–related orphan receptor (ROR) γt during positive selection, similar to the block in positive selection in RORγt transgenic mice. In the absence of HDAC3, the RORC promoter was hyperacetylated. In the periphery, the few CD4 T cells present were skewed toward RORγt+ IL-17–producing Th17 cells, leading to inflammatory bowel disease. Positive selection of CD8 single-positive thymocytes was restored in RORγt-KO Bcl-xL transgenic HDAC3-cKO mice, demonstrating that HDAC3 is required at positive selection to downregulate RORγt.
O-036 pufs safety and effectiveness outcomes by aneurysm shape
Becske, Tibor , Potts, Matthew B. , Brinjikji, Waleed , Kallmes, David F. , Shapiro, Maksim , Nelson, Peter K.

Mayo Clinic

Oral abstracts | June 8, 2016 | Volume: No volume available | Issue: No issue available | Pages: A19-A20

10.1136/neurintsurg-2015-011917.36 Get It

Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer
Papadopoulos, Kyriakos P. , Patnaik, Amita , Rascoe, Drew, Smith, Lon, Bullock, Andrea J. , Monga, Manish, Lin, Chester, Tsai, Lin-Feng, Elekes, Agnes, Ohi, Naoto, Tatsumi, Kunihiko, Coté, Gregory M. , Flaherty, Keith T. , Shapiro, Geoffrey I. , Berlin, Jordan D. , Habermann, Thomas M. , Witzig, Thomas E. , Ohi, Naoto, Tolcher, Anthony W.

Mayo Clinic

Molecular Cancer Therapeutics | May 20, 2016 | Volume: 14 | Issue: 12_Supplement_2 | Pages: B118-B118

10.1158/1535-7163.targ-15-b118 Get It

Abstract Background: OPB-111077 is a new chemical entity with anticancer activity in vitro and in human tumor xenograft models. The compound modulates STAT3 phosphorylation but has no marked effect on activity of any of 69 tested human tyrosine or serine/threonine kinases. This P1 study evaluated safety, pharmacokinetics, and antitumor activity of OPB-111077 in subjects with advanced cancers. Methods: Primary objectives determined safety, tolerability, and maximum tolerated dose (MTD) of OPB-111077 given orally once daily to subjects with advanced cancer. Secondary objectives included pharmacokinetics (PK) and antitumor activity. In the first 2 cycles of dose escalation, Day 1 dose was followed by 2 days off study therapy for PK. The starting dose was 100 mg once daily. Single subject cohorts with dose level doublings were studied until the first ≥ Grade 2 AE that was possibly drug-related. Then a 3+3 design was used. After MTD determination, expansion cohorts were opened for subjects with malignancies possibly susceptible to inhibition by OPB-111077, including breast, cervical, colorectal, gastric, kidney, myeloma, non-small cell lung, non-Hodgkin's lymphoma, ovarian, and prostate cancers, as well as “rare tumors” for which STAT3 inhibition might generate clinical activity. Results: Overall 145 subjects received OPB-111077. Mean age was 61 years (range 21-88), and 51% of subjects were female. Dose escalation occurred in 18 subjects. Four DLTs were observed: 2 at 400 mg QD (G3 nausea/vomiting), and 2 at 300 mg QD (G3 vertigo and G3 nausea/vomiting). The MTD was 250 mg QD. All subjects recovered from DLTs after drug discontinuation. Adverse events (AEs) that may be attributable to OPB-111077 include nausea (71%), vomiting (46%), fatigue (44%), dizziness/vertigo (26%), and hypothyroidism (19%). Most AEs were CTCAE Grades 1 or 2 and manageable with supportive treatment. OPB-111077 exposures increase dose proportionally and linearly with increasing single and multiple doses up to 250 mg. Median time to peak plasma concentration (tmax) is about 4 hours. Mean maximum plasma concentration (Cmax) is 16 μmol/L and mean trough concentration is 6 μmol/L after multiple doses of 250 mg QD. Terminal half-life is about 23 hours and steady state was reached by about 1 week. The major metabolites in plasma are pharmacologically inactive and unlikely to contribute to efficacy. Administration with a high fat meal did not significantly alter OPB-111077 bioavailability. Expansion cohorts enrolled 127 subjects, including NSCLC (13), breast (13), ovarian (11), kidney (11), colorectal (10), prostate (8), lymphoma (8), gastric (7), cervical (3) cancers, and myeloma (1). Rare tumors with STAT rationale included sarcomas (13), neuroendocrine tumors (7), squamous cell carcinomas (5), other carcinomas (12), and other malignant tumors (5). One RECIST Partial Response occurred in a subject with Diffuse Large B Cell Lymphoma. In addition, 7 subjects with had stable disease for at least 8 treatment cycles, including gastric (2), cholangiocarcinoma, kidney, prostate, K-Ras mutant colon cancer, and esthesioneuroblastoma. Conclusions: OPB-111077 can be given safely and achieves clinically active drug levels in humans. Single agent clinical activity was observed. Translational work is ongoing to determine factors driving clinical activity Citation Format: Gregory Cote, Kyriakos Papadopoulos, Amita Patnaik, Drew Rascoe, Lon Smith, Andrea Bullock, Keith Flaherty, Geoffrey Shapiro, Jordan Berlin, Manish Monga, Thomas Habermann, Thomas Witzig, Chester Lin, Lin-Feng Tsai, Agnes Elekes, Naoto Ohi, Kunihiko Tatsumi, Anthony Tolcher. A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118.
NKAP Regulates Invariant NKT Cell Proliferation and Differentiation into ROR-γt–Expressing NKT17 Cells
Thapa, Puspa , Chen, Meibo W., McWilliams, Douglas C., Belmonte, Paul , Constans, Megan, Sant’Angelo, Derek B. , Shapiro, Virginia Smith , Belmonte, Paul J

Mayo Clinic

The Journal of Immunology | May 10, 2016 | Volume: 196 | Issue: 12 | Pages: 4987-4998

10.4049/jimmunol.1501653 | PMID 27183586 Get It

Abstract Invariant NKT (iNKT) cells are a unique lineage with characteristics of both adaptive and innate lymphocytes, and they recognize glycolipids presented by an MHC class I–like CD1d molecule. During thymic development, iNKT cells also differentiate into NKT1, NKT2, and NKT17 functional subsets that preferentially produce cytokines IFN-γ, IL-4, and IL-17, respectively, upon activation. Newly selected iNKT cells undergo a burst of proliferation, which is defective in mice with a specific deletion of NKAP in the iNKT cell lineage, leading to severe reductions in thymic and peripheral iNKT cell numbers. The decreased cell number is not due to defective homeostasis or increased apoptosis, and it is not rescued by Bcl-xL overexpression. NKAP is also required for differentiation into NKT17 cells, but NKT1 and NKT2 cell development and function are unaffected. This failure in NKT17 development is rescued by transgenic expression of promyelocytic leukemia zinc finger; however, the promyelocytic leukemia zinc finger transgene does not restore iNKT cell numbers or the block in positive selection into the iNKT cell lineage in CD4-cre NKAP conditional knockout mice. Therefore, NKAP regulates multiple steps in iNKT cell development and differentiation.